- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03341637
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The vaccine tested in this study was tetravalent dengue vaccine (TDV). TDV was tested to assess the safety and immunogenicity in healthy adolescents in non-endemic area(s) for dengue.
The study enrolled 400 healthy participants. Participants were randomized in 3:1 ratio to receive:
- TDV 0.5 mL subcutaneous injection
- Placebo normal saline solution (0.9% NaCl) for injection.
In each trial group, participants received 2-dose schedule of TDV or placebo by subcutaneous injection on Days 1 (Month 0) and 90 (Month 3), but not all participants received both doses (8 subjects discontinued the trial before receiving the second dose).
This multi-center trial was conducted in Mexico. The overall time to participate in this study was 270 days. Participants had multiple visits to the clinic including a final visit at Day 270.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Ciudad de Mexico, Mexico, 09360
- Biodextra, S.A. de C.V.
-
Mexico City, Mexico, 06720
- Hospital Infantil de Mexico Federico Gomez
-
Mexico City, Mexico, 04530
- Instituto Nacional de Pediatría (INP)
-
Mexico City, Mexico, ZC 03100
- Mexico Centre for Clinical Research
-
Mexico City, Mexico
- Centro de Atencion E Investigacion Medica (CAIMED) Mexico DF
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- The participant is aged 12 to 17 years, inclusive;
- Is in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and the clinical judgment of the Investigator.
- The participant/the participant's legally authorized representative (LAR) signs and dates a written, informed consent/assent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.
- Individuals who can comply with trial procedures and are available for the duration of follow-up.
Exclusion Criteria:
- Has an elevated oral temperature (≥38°C or 100.4°F) within 3 days of the intended date of vaccination.
- Known hypersensitivity or allergy to any of the vaccine components.
- Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the trial.
- Has any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (e.g., Guillain-Barre syndrome).
- History or any illness that, in the opinion of the Investigator, might interfere with the results of the trial or pose additional risk to the participant due to participation in the trial.
Has known or suspected impairment/alteration of immune function, including:
- Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (M0) (use of inhaled, intranasal, or topical corticosteroids is allowed).
- Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥ 2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (M0).
- Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (M0) or planned administration during the trial.
- Receipt of immune-stimulants within 60 days prior to Day 1 (M0).
- Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (M0).
- Human immunodeficiency virus (HIV) infection or HIV-related disease.
- Genetic immunodeficiency.
- Has abnormalities of splenic or thymic function.
- Has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding.
- Has any serious chronic or progressive disease according to judgment of the Investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
- Has body mass index (BMI) greater than or equal to 35 kg/m^2 (= weight in kg/[height in square meters]).
- Individuals participating in any clinical trial with another investigational product 30 days prior to Day 1 (M0) or intent to participate in another clinical trial at any time during the conduct of this trial.
- Has received any other vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial or who are planning to receive any vaccine within 28 days of trial vaccine administration.
- Individuals involved in the trial conduct or their first degree relatives.
- Has history of substance or alcohol abuse within the past 2 years.
- Female participants who are pregnant or breastfeeding.
- Females of childbearing potential who are sexually active, and who have not used any of the acceptable contraceptive methods for at least 2 months prior to Day 1 (M0).
- Females of childbearing potential who are sexually active, and who refuse to use an acceptable contraceptive method up to 6 weeks after the last dose of trial vaccine. In addition, they must be advised not to donate ova during this period.
- Any positive or indeterminate pregnancy test.
- Previous and planned vaccination (during the trial conduct), against any flaviviruses including dengue, yellow fever (YF), Japanese encephalitis (JE) viruses or tick-borne encephalitis.
- Previous participation in any clinical trial of a dengue or other flavivirus (eg, West Nile [WN] virus) candidate vaccine, except for participants who received placebo in those trials.
- Participants with documented or suspected disease caused by a flavivirus such as dengue, Zika, YF, JE, WN fever, tick-borne encephalitis or Murray Valley encephalitis.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Tetravalent Dengue Vaccine (TDV)
TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
|
TDV subcutaneous injection
|
Placebo komparator: Placebo
TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
|
Normal saltvand (0,9% NaCl) subkutan injektion
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120
Tidsramme: One month post second dose (Day 120)
|
GMTs of neutralizing antibodies were measured by microneutralization test 50% [MNT50] for each of the 4 Dengue Serotypes.
The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
Seropositivity is defined as reciprocal neutralizing titer ≥10.
|
One month post second dose (Day 120)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270
Tidsramme: Six months post second dose (Day 270)
|
GMTs of neutralizing antibodies were measured by microneutralization test 50% [MNT50] for each of the 4 Dengue Serotypes.
The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
Seropositivity is defined as reciprocal neutralizing titer ≥10.
|
Six months post second dose (Day 270)
|
Seropositivity Rates for Each of the 4 Dengue Serotypes
Tidsramme: One month and six months post second dose (Day 120 and Day 270)
|
Seropositivity rate, defined as the percentage of participants seropositive, was derived from the titers of dengue-neutralizing antibodies.
Seropositivity defined as a reciprocal neutralizing titer ≥10.
The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3 and DENV-4.
|
One month and six months post second dose (Day 120 and Day 270)
|
Seropositivity Rates for Multiple (2, 3 or 4) Dengue Serotypes
Tidsramme: One month and six months post second dose (Day 120 and Day 270)
|
Seropositivity rate, defined as the percentage of participants seropositive, was derived from the titers of dengue-neutralizing antibodies.
Seropositivity was defined as a reciprocal neutralizing titer ≥10.
|
One month and six months post second dose (Day 120 and Day 270)
|
Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary Recorded) Following Each Vaccination by Severity
Tidsramme: Within 7 days after each vaccination
|
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents daily activity with or without treatment), redness (erythema) (<2.5 cm, mild: 2.5-5 cm, moderate: >5 to <=10 cm, severe: >10 cm) and swelling (edema/induration) (<2.5 cm, mild: 2.5-5 cm, moderate: >5 to <=10 cm, severe: >10 cm).
|
Within 7 days after each vaccination
|
Percentage of Participants With Solicited Systemic Adverse Events (AEs) (Diary Recorded) Following Each Vaccination by Severity
Tidsramme: Within 14 days after each vaccination
|
Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and included fever, headache, tiredness or weakness (asthenia), feeling of discomfort (malaise) and muscle pain (myalgia).
Severity scales for headache were none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents normal activity with or without treatment.
Severity scales for others were none, mild: no interference with daily activity, moderate: interference with daily activity and severe: prevents daily activity.
A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 14 days after vaccination.
Fever was excluded from the overall count as no severity grading was applied for it.
|
Within 14 days after each vaccination
|
Percentage of Participants With Any Unsolicited Adverse Events (AEs) Following Each Vaccination
Tidsramme: Within 28 days after each vaccination
|
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
|
Within 28 days after each vaccination
|
Percentage of Participants With Medically Attended AEs (MAAEs) Throughout the Study
Tidsramme: From first vaccination (Day 1) through end of study (Day 270)
|
MAAEs were defined as AEs leading to a medical visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
|
From first vaccination (Day 1) through end of study (Day 270)
|
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
Tidsramme: From first vaccination (Day 1) through end of study (Day 270)
|
An SAE was defined as any untoward medical occurrence or effect that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.
|
From first vaccination (Day 1) through end of study (Day 270)
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- DEN-315
- U1111-1192-7827 (Anden identifikator: World Health Organization)
- RNEC-2017-DEN-315 (Registry Identifier: Mexico)
- 2018-003980-77 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Tetravalent Dengue Vaccine (TDV)
-
TakedaAfsluttetDengue feberForenede Stater
-
TakedaAfsluttetDengue feberFilippinerne, Dominikanske republik, Panama
-
TakedaAktiv, ikke rekrutterendeSunde frivilligeThailand, Brasilien, Colombia, Dominikanske republik, Nicaragua, Panama, Filippinerne, Sri Lanka
-
TakedaAfsluttet
-
TakedaAfsluttet
-
Inviragen Inc.Afsluttet
-
TakedaAfsluttet